What is Castle Biosciences's total equity?

Castle Biosciences (CSTL) reported total equity of $461.42M in Q1 2026.

How has Castle Biosciences's total equity changed year-over-year?

Castle Biosciences's total equity increased by 4.8% year-over-year, from $440.31M to $461.42M.

What is the long-term trend for Castle Biosciences's total equity?

Over 5 years (2020 to 2025), Castle Biosciences's total equity has grown at a 2.5% compound annual growth rate (CAGR), from $415.69M to $470.87M.

What does total equity mean?

Net assets attributable to shareholders — total assets minus total liabilities. Represents the book value of shareholders' ownership claim.

Castle Biosciences CSTL Total Equity

Total Equity at other companies

Labcorp HoldingsLH

$8.73B+5.1%

VeracyteVCYT

$1.34B+12.5%

Personalis, Inc.PSNL

$254.77M+22.9%

NeoGenomicsNEO

$828.76M-6.7%

Fulgent Genetics, Inc.FLGT

$1.05B-6.9%

Cogent Biosciences, Inc.COGT

$607.69M+177%

Other financials

Income statement

See full

Revenue$83.7M-4.9%

Gross profit$63.1M-11.8%

Operating income-$18.4M+34.1%

Net income-$14.5M+43.8%

EPS (diluted)-$0.49+45.6%

Balance sheet

See full

Cash & equivalents$63.8M-28.9%

Total debt$36.7M+42.1%

Total assets$547.8M+9.2%

Cash flow

See full

Operating cash flow-$22.1M-267%

CapEx$12.5M+163%

Free cash flow-$34.6M-221%

Valuation

See full

Market cap$694.86M+29.9%

Enterprise value$667.82M+41.8%

P/S2×+0.5×

Profitability

See full

Gross margin77.9%-4.1pp

Operating margin-9.8%-30.8pp

Net margin-3.8%-10.2pp

FCF margin1.3%-10.7pp

Returns & leverage

See full

Return on equity-2.8%-10.6pp

Debt / equity0.1×0.0×

Current ratio6.7×-2.6×

Where this comes from

Reported directly by Castle Biosciences in its filing.

Tagged under the XBRL concept us-gaap:StockholdersEquity.

The official record: Castle Biosciences’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →

Ask your AI about Castle Biosciences's total equity.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Castle Biosciences's total equity?: Castle Biosciences (CSTL) reported total equity of $461.42M in Q1 2026.
How has Castle Biosciences's total equity changed year-over-year?: Castle Biosciences's total equity increased by 4.8% year-over-year, from $440.31M to $461.42M.
What is the long-term trend for Castle Biosciences's total equity?: Over 5 years (2020 to 2025), Castle Biosciences's total equity has grown at a 2.5% compound annual growth rate (CAGR), from $415.69M to $470.87M.
What does total equity mean?: Net assets attributable to shareholders — total assets minus total liabilities. Represents the book value of shareholders' ownership claim.